Dr. Abdel-Moneim Mahmoud Ali Osman
My Social Links

Dr. Abdel-Moneim Mahmoud Ali Osman

King Abudulaziz University, Saudi Arabia

Highest Degree
PostDoc Fellow in Cancer Research from University of Amsterdam, The Netherlands

Share this Profile


Dr. Abdel-Moneim Mahmoud Ali Osman holds a position of Professor at Cancer Institute, Cairo University and Deputed to the College of Medicine, King Abdel-Aziz University. He has completed his Post Doctoral Fellow in Cancer Research from University of Amsterdam, The Netherland, and PhD Pharmacology in College of Medicine, University of Amsterdam, Holland in 1985. He has published 79 research articles in journals contributed as author/co-author. He also completed 6 projects as Principal Investigator. He successfully supervised 25 Masters and 17 PhD thesis.

Area of Interest:

Pharmacology and Toxicology
Tissue Culture
Anticancer Activity

Research Publications in Numbers


Selected Publications

  1. Osman, A.M.M., S.E. Al-Harthy, R.M. Mohamed, E.A. Huwait, H.M. Al-Kreathy, M. Alkhaled and M.M. Sayed-Ahmed, 2019. Dimethyl sulfoxide potentiates the anticancer activity of cisplatin against the growth of lung cancer cells. Int. J. Pharmacol., 15: 586-592.
    CrossRef  |  Direct Link  |  
  2. AlQahtani, A.A., Abdel-Moneim M. Osman, H.M. Al-Kreathy and S.E. Al-Harthy et al., 2019. Chemosensitizing effects of marine astaxanthin on the anti-cancer activity of doxorubicin in tumor bearing mice. Int. J. Cancer Res., 15: 1-8.
    CrossRef  |  Direct Link  |  
  3. AlQahtani, A.A., A.M.M. Osman, Z.A. Damanhouri, H.M. Al-Kreathy and H.S. Al-Malky et al., 2019. Cardioprotective effect of marine astaxanthin on doxorubicin-induced cardiotoxicity in normal rats. J. Pharm. Res. Int., 27: 1-11.
    CrossRef  |  Direct Link  |  
  4. Al-Malky, H.S., A.M.M. Osman, Z.A. Damanhouri, H.M. Alkreathy and J.Y. Al Aama et al., 2019. Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against cardiotoxicity in experimental animals. Cancer Cell Int., Vol. 19. 10.1186/s12935-019-0912-0.
    CrossRef  |  Direct Link  |  
  5. Al-Harthy, S.E., M.S. Al-Motairi, H.M. Al-Kreathy, F.O. Kamel and M.M. Sayed-Ahmed et al., 2019. Enhancement of doxorubicin cytotoxicity by verapamil in human breast cancer cells. J. Pharm. Res. Int., 27: 1-10.
    CrossRef  |  Direct Link  |  
  6. Osman, A.M.M., H.M. Al-Kreathy, A. Al-Zahrani, O.A. Ahmed and W.S. Ramadan et al., 2017. Enhancement of efficacy and reduced toxicity of cisplatin through Self Nanoemulsifying Drug Delivery System (SNEDDS). Int. J. Pharmacol., 13: 292-302.
    CrossRef  |  Direct Link  |  
  7. Khan, L.M., F.O. Kamel, H.M. Alkreathy, S.E. Al-Harthi, O.I. Saadah, A.M.M. Osman and M.A. Allibaih, 2017. Benefits of medication antidote signals for the detection of potential adverse drug reactions over contemporary methods of pharmacovigilance in hospitalized children. Int. J. Pharmacol., 13: 64-73.
    CrossRef  |  Direct Link  |  
  8. Khan, L.M., S.E. Al-Harthi, A.M.M. Osman, M.A.A.A. Sattar and A.S. Ali, 2016. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharmaceut. J., 24: 485-493.
    CrossRef  |  Direct Link  |  
  9. Aly, H.A., M.H. Hassan, H.A. El-Beshbishy, A.M. Alahdal and A.M.M. Osman, 2016. Dibutyl phthalate induces oxidative stress and impairs spermatogenesis in adult rats. Toxicol. Ind. Health, 32: 1467-1477.
    CrossRef  |  Direct Link  |  
  10. Abdel-Alim, H.M., H. Abdel-Dayem, B.T.J. Aboms, G. Zuelhemma and A.M. Osman, 2016. The chemopreventive role of aged garlic extract against chemically induced tongue carcinogenesis. Int. J. Bioassays, 5: 4836-4841.
  11. Osman, A.M.M., S.A. Telity, Z.A. Damanhouri, S.E. Al-Harthy and H.M. Al-Kreathy et al., 2015. Chemosensitizing and nephroprotective effect of resveratrol in cisplatin-treated animals. Cancer Cell Int., Vol. 15. 10.1186/s12935-014-0152-2.
    CrossRef  |  Direct Link  |  
  12. Osman, A.M.M., H.S. Al-Malki, S.E. Al-Harthi, A.A. El-Hanafy, H.M. Elashmaoui and M.F. Elshal, 2015. Modulatory role of resveratrol on cytotoxic activity of cisplatin, sensitization and modification of cisplatin resistance in colorectal cancer cells. Mol. Med. Rep., 12: 1368-1374.
    CrossRef  |  PubMed  |  Direct Link  |  
  13. Osman, A.M.M., A.A. Ali, Z.A. Damanhouri, S.E. Al-Harthy and M.F. ElShal et al., 2015. Dimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cells. Cancer Cell Int., Vol. 15. 10.1186/s12935-015-0258-1.
    CrossRef  |  Direct Link  |  
  14. Khan, L.M., S.E. Al-Harthi, A.M. Osman, M.A. Alim, A. Sattar and A.S. Ali, 2015. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm. J., .
  15. Aly, H.A.A., M.H. Hassan, H.A. El-Beshbishy, A.M. Alahdal and A.M. Osman, 2015. Dibutyl phthalate induces oxidative stress and impairs spermatogenesis in adult rat. Toxicol. Ind. health, 2015: 1-11.
  16. Al-Harthi, S.E., L.M. Khan, A.M. Osman, M.A. Alim, O.I. Saadah, A.A. Almohammadi, F.M. Khan and F.O. Kamel, 2015. Perceptions and knowledge regarding antimicrobial stewardship among clinicians in Jeddah, Saudi Arabia. Saudi Med. J., 36: 813-820.
    CrossRef  |  Direct Link  |  
  17. Khan, L.M., S.E. Al-Harthi, H.M. Alkreathy, A.M. Osman and A.S. Ali, 2014. Detection of adverse drug reactions by medication antidote signals and comparison of their sensitivity with common methods of ADR detection. Saudi Pharm. J., 23: 515-522.
    Direct Link  |  
  18. Al-Harthi, S.E., O.M. Alarabi, W.S. Ramadan, M.N. Alaama, H.M. Al-Kreathy, Z.A. Damanhouri, L.M. Khan and A.M. Osman, 2014. Amelioration of doxorubicin-induced cardiotoxicity by resveratrol. Mol. Med. Rep., 10: 1455-1460.
    Direct Link  |  
  19. Osman, A.M., S.E. Al-Harthi, O.M. AlArabi, M.F. Elshal, W.S. Ramadan, M.N. Alaama, H.M. Al-Kreathy, A. Zoheir, Damanhouri and O.H. Osman, 2013. Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals. Cancer Cell Int., 13: 52-52.
  20. Abdallah, H.M., A.M.M. Osman, H. Almehdar and E. Abdel-Sattar, 2013. Acylated pregnane glycosides from Caralluma quadrangular. Phytochemistry, 88: 54-60.
    CrossRef  |  Direct Link  |  
  21. Osman, A.M., M.H. Bayoumi, E. Sameer, A. Al-Harthi, A. Zoheir, Damanhouri and M.F. ElShal, 2012. Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int., 12: 47-52.
  22. Almehdar, H., H.M. Abdallah, A.M.M. Osman and E.A. Abdel-Sattar, 2012. In vitro cytotoxic screening of selected Saudi medicinal plants. J. Nat. Med., 66: 406-412.
    CrossRef  |  Direct Link  |  
  23. Alkreathy, H.M., Z.A. Damanhouri, N. Ahmed, M. Slevin and A.M. Osman, 2012. Mechanisms of cardioprotective effect of aged garlic extract against doxorubicin-induced cardiotoxicity. Integr. Cancer Ther., 11: 364-370.
    CrossRef  |  PubMed  |  Direct Link  |  
  24. Osman, A.M.M., M.I. Sulaiman and Z.A. Damanhouri, 2011. Cytotoxic effect of dexamethasone restricted tononcycling, early G1 phase of melanoma cells. J. Cancer Ther., 2: 253-257.
    CrossRef  |  Direct Link  |  
  25. Ali, A., F. Khorshid, H. Abu-Araki and A.M. Osman, 2011. Tumor lung cancer model for assessing anti-neoplastic effect of pmf in rodents: Histopathological study. Trends Applied Sci. Res., 6: 1214-1221.
    CrossRef  |  
  26. Osman, A.M.M., O.A. Nasseir and N.R. Ismail, 2010. Potential mechanism for the effects of dexamethasoneon growth of human melanoma cells in vitro. Health, 2: 857-861.
    CrossRef  |  Direct Link  |  
  27. Alkreathy, H., Z.A. Damanhouri, N. Ahmed, M. Slevin, S.S. Ali and A.M.M. Osman, 2010. Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food Chem. Toxicol., 48: 951-956.
    CrossRef  |  Direct Link  |  
  28. Osman, A.M.M., A.A. Abdel-Fatah, B.B. Hassan, M.M. El-Merzebani and Z.A. Damanhouri, 2009. Effect of protein depletion on host and tumor response to paclitaxel in experimental animals. Int. J. Pharmacol., 5: 173-177.
    CrossRef  |  Direct Link  |  
  29. Osman, A.M., M.M. Nemnem, A.A. Abou-Bakr, O.A. Nassier and M.T. Khayyal, 2009. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice. Food Chem. Toxicol., 47: 2425-2430.
    PubMed  |  
  30. Khorshid, F.A., A.M. Osman and E. Abdel-Sattar, 2009. Cytotoxic activity of bioactive fractions from PM701. EJEAF Chem., 8: 1091-1098.
  31. El-Abhar, H.S., O.A. Ahmedy, A.M.M. Osman and A.A. Shoka, 2009. Potential modulatory effect of selenium on the antitumor activity and toxicity of doxorubicin in tumor-bearing mice. Az. J. Pharm. Sci., 39: 183-199.
  32. Kamel, M.W., S.A. Salama, S. Saleh, A.M.M.Osman, M.S. Ahmed and A. Al-Hendy, 2007. Reversal of doxorubicin resistance by adenovirus-mediated transfer of cyclooxygenase-2 antisense in multidrug-resistant MCF-7 cells. Cancer Therapy, 5: 1-10.
  33. Arafa, H.M.M., M.A. Abdel-Hamid, A.A.K. El-Khouly, M.M.A. El-Mazar and M. Osman, 2006. Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology, 222: 103-113.
    CrossRef  |  
  34. Azab, S.S., E. El-Demardash, A. Abdel-Naim, E. Youssef, N. El-Sharkawy and A.M. Osman, 2005. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cell lines. Biochem. Parmacol., 70: 725-732.
    Direct Link  |  
  35. Sayed-Ahmed, M.M., M. Eissa, S. Kenawy, N. Mostafa, M. Calvani and A.M. Osman, 2004. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy, 50: 162-170.
    CrossRef  |  Direct Link  |  
  36. Gabri, M.S., A.M. Osman, M.M. El-Sayed and S. Negm, 2004. Prophylactic effect of tamoxifen against induction of mammary Carcinoma. Egyp. J. Hospital Med., 14: 104-114.
  37. El-Demerdash, E., A. Abdel-Fatah, M.M. Sayed-Ahmed and A.M. Osman, 2003. New aspects in probucol cardioprotection against doxorubicin induced cardiotoxicity. Cancer Chemother. Pharmacol., 52: 411-416.
    Direct Link  |  
  38. Al-Demardash, E., E. El-Denshary, M. El-Didi, N. Al-Gharabli and A.M. Osman, 2001. Probucol and liver efficiency during hepatocarcinogenesis. Anticancer Res., 22: 977-984.
    Direct Link  |  
  39. Ahmed, M.S., M.K.M. Zakeria and A.M. Osman, 2001. Plasma Endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol. Toxicol., 88: 515-522.
  40. Sayed-Ahmed, M.M., S.A. Shouman, B.M. Rezk, M.H. Khalifa, A.M. Osman and M.M. El-Merzabani, 2000. Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid β-oxidation in isolated heart mitochondria. Pharmacol. Res., 41: 143-150.
  41. Osman, A.M., S.M. Abou-gofa and E.E. Zaki, 2000. The protective effect of methimazole against cisplatin-induced nephrotoxicity. Pharmacol. Res., 41: 115-119.
  42. Osman, A.M., M.A. Mohamed, A.A. Abdel-Wahab and M.S. Ahmed, 2000. Modulation by verapamil of doxorubicin induced expression of multidrug resistance gene (mdr-1/P-glycoprotein) in murine tumour cells. J. Egypt. Nat. Cancer Inst., 12: 221-227.
    Direct Link  |  
  43. Osman, A.M., H. Gaballa, N.H. Mohamed, N.M. Ali, M.S. Ahmed and H.M. Arafa, 2000. Plasma endothelin (ET-1) as a marker for doxorubicin-induced cardiotoxicity in egyptian patients. J. Egypt Soc. Toxicol., 23: 59-64.
  44. Sayed-Ahmed, M.M., S. Sharawy, S.A. Shouman and A.M. Osman, 1999. Reversal of doxorubicin-induced cardiac metabolic damage by l-carnitine. Pharmacol. Res., 33: 289-295.
  45. Sayed-Ahmed, M.M., M. Khattab, A. Khalifa, M. El-Khabany and A.M. Osman, 1999. Potential promise of using L-carnitine and Coenzyme Q10 as protective agents against Cisplatin-induced nephrotoxicity. J. Egypt. National Cancer Inst., 11: 167-173.
  46. Khalifa, A.S., B. Fahim, G. Mokhtar, N. El-Beblawy and W. Ezzat et al., 1999. Different modalities of methotrexate therapy in acute childhood lymphoblastic leukemia. Egypt. J. Paediatr., 16: 105-112.
  47. Hanafy, M., S.M.M. Ahmed and A.M. Osman, 1999. The protective effect of methimazole against cisplatin-induced chromosomal abberrations. Sci. J. Az. Med. Fac.(Girls), 20: 637-645.
  48. El-Tannir, O.M., K. El-Sabban and A.M. Osman, 1998. Role of I131, MIBG assessment of neuroblastoma in children at NCI, Egypt. J. Egyp. National Cancer Institute, 10: 341-347.
  49. Abidli, N., M.M. Sayed-Ahmed, S.M. El-Gerzawy, M.M. El-Didi and C. Benlatreche et al., 1998. Verapamil enhancement of the cytotoxic and cell cycle perturbation of doxorubicin in Ehrlich ascites carcinoma cells in vivo. J. Egypt. National Cancer Inst., 10: 433-438.
  50. Osman, A.M., S.T. Al-sedairy and I.M. Moran, 1996. Verapamil enhancement of antitumour effect of cisdiamminodichloroplatin(II) in mouse bearing ehrlich ascites carcinoma cells. Med. Sci. Res., 24: 429-431.
  51. Al-Shabanah, O.A., A.M. Osman, M.M. Sl-Harbi, N.M. AL-Gharably and A.M. AL Bekairi, 1996. Effect of hyperthermia on the action of methotrexate against the growth of Ehrlich ascites carcinoma cells. Med. Sci. Res., 24: 275-277.
  52. Al-Shabanah, O.A., A.M. Osman, M.M. Al-Harbi, A.M. Al-Bekairi, N.M. Al-Gharably and S.A. Aziz, 1995. Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites carcinoma cells. Chemotherapy, 41: 368-377.
    PubMed  |  
  53. Al-Harbi, M.M., A.M. Osman and A.M. Al-Gharably, 1995. Effect of desferrioxamine on cisplatin-induced nephrotoxicity in normal rats. Chemotherapy, 41: 448-454.
  54. Osman, A.M., S. Saad and S.Y. Saad, 1994. Pharmacokinetic profile of methotrexate and 5-flurouracil in normal and bilharzial infested mice. Chemotherapy, 40: 227-231.
  55. Osman, A.M., O. Al-Shabanah and M.M. Al-Harbi, 1994. Protective effect of desferrioxamine against doxorubicin-induced lethality and nephrotoxicity in mice. J. Biomed. Sci. Ther., 10: 99-112.
  56. Eid, F., A. El-Aser, N. Farid and A.M. Osman, 1994. Evaluation of the protective role of thiola and WR-2721 against biological effect of radiation. Egypt. J. Rad. Sci. Appl., 70: 19-30.
  57. Al-Shabanah, O., A.M. Osman and M. Al Harbi, 1994. Enhancement of doxorubicin-induced cytotoxicity by hyperthermia in Ehrlich ascites cells. Chemotherapy, 40: 188-194.
  58. Osman, A.M., O.A. Al-Shabanah and M.M. Al-Harbi, 1993. Effect of desferrioxamine on doxorubicin-induced cardiotoxicity and haematotoxicity in mice. Med. Sci. Res., 21: 193-194.
  59. Osman, A.M., M.M. Ahmed, M.T. Khyyal and M.M. El-Merzabani, 1993. Hyperthermic potentiation of cisplatin cytotoxicity on solid Ehrlich carcinoma. Tumori, 79: 268-272.
    PubMed  |  Direct Link  |  
  60. Osman, A.M., A.A. El-Aaser and M.M. El-Merzebani, 1993. Protection and potentiation of methanesulfonate cytotoxicity by WR 2721 and Thiola. J. Egypt. Soc. Pharm. Exp. Ther., 4: 81-92.
  61. Hamada, F.M. and A.M. Osman, 1993. The oncolytic activity and effect on bone marrow cellular elements of methotrexate-cinnarine and mitomycin C-verapamil combinations EAC-bearing mice. Egypt. J. Tumour Marker Oncol., 4: 1-7.
  62. Hamada, F., A.M. Osman and A.H. Abdel-Aziz, 1993. Ca+2 antagonist enhance the cytotoxicity of anticancer agent.The effect of verapamil and cinnerizine on cellular transport of (14 C) mitomycin C and (3 H) methotrexate. Egypt. J. Tumour Marker Oncol., 4: 81-92.
  63. Hamada, F., A.M. Osman and A. Hamed, 1993. Experimental study to improve the therapeutic efficacy of cisplatin. Egypt. J. Tumour Marker Oncol., 4: 51-67.
  64. Al-Gharably, N.M., A.M. Osman and O. Al-Shabanh, 1993. Potentiation of doxorubicin cytotoxicity by the calcium channel blocker verapamil in Ehrlich Ascites cells. Chemotherapy, 39: 410-415.
  65. Al-Bekairi, A.M., A.M. Osman and M.A. Hafeez, 1993. Effect of desferrioxamine on the hepatotoxicity of adriamycin in normal mice. Drug Dev. Res., 29: 56-62.
  66. Mossa, M.A., A.M. Osman, M. El-Sayed, A.A. El-Aaser, N. Ismael and M.M. El-Merzabani, 1992. Distribution and toxicity of 5-flurouracil after intraperitoneal and anal submucosal adminstration. J. Pharm. Belg., 47: 129-134.
    PubMed  |  
  67. Al-Harbi, M., O. Al-Shabanh, M. Al-Gharably, A.M. Osman and H.N. Tawfik, 1992. Prevention of doxorubicin-induced myocardial haematological toxicity in rats by iron chelator desferrioxamine. Cancer Chemoth. Pharmacol., 31: 200-204.
    Direct Link  |  
  68. Sharaf, E., A.M. Osman and L.A. Smets, 1991. Kinetics of dexamethasone-binding in leukemic cells in presence and absence of meta-iodobenzylguanidine (MIBG) and nicotinamide. J. Egypt. Natl. Cancer Institute, 5: 147-154.
  69. Osman, A.M., N.A. Kinawi and M.A. Attia, 1991. Effect of methotrexate and adrenaline on the rate 3H-thymidine incorporation protein and mitotic index of rabbit epithelium of platine mucosa. J. Egypt. Soc. Pharmacol Exp. Ther., 1: 431-441.
  70. Osman, A.M., N. Ismail and S. Shoman, 1991. Modulation of dexamethasone effect in butyrate-treated melanoma cells. J. Bio. Med. Sci. Ther., 7: 613-623.
  71. Saleh, S., M.M. El-Merzebani, S. Fahmy and A.M. Osman, 1990. Improving effect of the cytotoxic drug methotrexate with the non-narcotic analgesic lysine acetyl salicylic acid. J. Egypt. Soc. Pharmacol. Ther., 2: 451-478.
  72. Saad, S.F., M.M. El-Merzabani, S. Saleh and A.M. Osman, 1990. The possible beneficial effect of cancer treatment with methotrexate in combination with the narcotic analgesic butorphenol tartarate. J. Egypt. Soc. Pharmacol. Exp. Ther., 9: 479-504.
  73. Osman, M.I., M.K. Abou El-Ghate and A.M. Osman, 1990. The influence of total intravenous anaesthesia with propofol on neonata status in elective Caesarean section, a comparative study with conventional anaesthesia. Egypt. J. Anaesth, 6: 57-61.
  74. Moharram, M., S. Mansour and A.M. Osman, 1990. Reactions with purine derivative. Synthesis of arylamino purines of antitumour effect. J. Pharm. Sci., 31: 487-494.
  75. El-Merzebani, M.M., A. El-Aaser and A.M. Osman, 1990. Studies on drug metabolizing enzyme activity levels in liver of normal and Schistosomal infected mice. J. Bio. Med. Sci. Ther., 6: 63-71.
  76. Ebeid, M.Y., S.M. El-Moghazy, A.A. Eissa and A.M. Osman, 1990. Regioselective synthesis and antitumour activity at 8-chloro-5-(P-N-Substituted sulfomoylphenyl)-aminobenzo (b)(1,8) naphthyridine. Egypt. J. Pharm. Sci., 31: 515-525.
  77. Moharram, H.H., K.A. Mayoum, B. Haggag, W.M. Basyouni and A.M. Osman, 1989. Synthesis and structure of purine dervivative as antitumour effect. Arch. Pharm. Res., 12: 138-142.
  78. Moharram, H.H. and A.M. Osman, 1989. Reaction of Purines derivatives with phosphorus pentaoxide and triethylamine and their antitumour effect. Arch. Pharm. Res., 12: 1-4.
  79. El-Merzabani, M.M., A.A. El-Aaser, A.M. Osman, 1989. Potentiation of therapeutic effect of methanesulphonate and protection against its organ cytotoxicity by vitamin C in Ehrlich ascites carcinoma bearing mice. J. Pharm. Belg, 44: 109-116.
  80. Osman, A.M., F.M. Hamada and A. Hamed, 1988. Interaction of cisplatin with some common analgesics in vitro and in vivo study on the oncolytic activity against EAC. Egypt. J. Med. Sci., 9: 339-353.
  81. Hamada, F.M., A.M. Osman and F. Abu El-Ela, 1988. Effective antineoplastic therapy consisting of cisplatin and analgesics. Egypt. J. Med. Sci., 9: 217-232.
  82. Awad, H.K., S. El-Badawy, H. Abdel-Baki, M. Zaghloul and A.M. Osman, 1988. Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer.Evidence of diffusion from urine. Int. J. Radiatn.Oncology Biol.Phys., 16: 1085-1086.
  83. Osman, A.M., 1987. Effect of melphalan on proliferation and cell cycle of human melanoma cells in vitro. J. Egypt. Natl. Cancer Institute, 3: 319-325.
  84. Osman, A.M. and T.M. Amer, 1987. Effect of L. Dopa on the growth of human melanoma cells in vitro. J. De Pharmacie de Belgique, 42: 323-326.
  85. Benckhuijsen, C., A.M. Osman, M.J. Hillebrand and L.A. Smets, 1987. Glucocorticoid effect on melphalan cytotoxicity, cell cycle position,cell size and (3H) uridine incorporation in one among three human melanoma cell lines. Cancer Res., 47: 4814-4820.
  86. Osman, A.M., T.A. Mohamed and M.M. Assem, 1986. Effect of ascorbic acid and melphalan on the growth of human melanoma cells. J. Egypt. Natl. Cancer Instituute, 3: 421-425.
  87. Osman, A.M., P.W. Jansen, L.A. Smets and C. Benckhuijsen, 1985. Glucocorticoid receptors and cell cycle progression in human melanoma cell lines. J. Cell. Phys., 125: 306-312.
  88. Moawad, H., S. Fahmy, M. El-Merzabani, A. El-Aaser and A.M. Osman, 1979. Comparative biopharmacological study on two related anticancer methanesulfonate of aminoglycols. Bull. Fac. Pharm., 18: 1153-1170.
  89. El-Merzabani, M.M., A.A. El-Aaser, A.M. OSMAN, H. Moawad and S. Fahmy, 1977. Effect of two anticancer methanesulfonate of aminoglycols on some liver phosphatases in normal, bilharzial and tumour-bearing mice. Bull. Fac. Pharm., 16: 75-83.